S haker-type voltage-gated K + (K V 1) channels composed of K V 1.2 and K V 1.5 α-subunits are expressed in cerebral vascular smooth muscle cells (cVSMCs), where they contribute to the resting diameter and vasodilation of cerebral arteries (CAs). 1,2 K V 1 channels are multiprotein structures composed of 4 K V α pore-forming subunits coassembled with intracellular K V β subunits, which may affect channel trafficking and kinetics. [3] [4] [5] [6] [7] [8] In addition, post-translational modifications, such as glycosylation and protein kinase A (PKA)-mediated phosphorylation of the K V α subunits, may increase protein expression and activity of K V 1 channels. [9] [10] [11] [12] [13] [14] [15] Recently, we reported the expression of a scaffolding protein, postsynaptic density protein-95 (PSD95), in rat CA. 16 Previously, PSD95 was studied primarily in neurons, where it provides an assembly platform at the plasma membrane for macromolecular signaling complexes including ion channels. 17-22 However, we reported that PSD95 serves as a molecular scaffold for K V 1 channels in cVSMCs, and this interaction is required for the proper expression of K V 1 channels that exerts a tonic vasodilator influence. 16 Accordingly, antisense-mediated knockdown of PSD95 in rat CA resulted in a loss of K V 1 channel expression and caused vasoconstriction, inferring that PSD95 promotes the expression of K V 1 channels in cVSMCs. 16 Notably, the C terminus of the K V 1.2α subunit contains a structural motif that permits the channel to interact with
PSD95. [16] [17] [18] [19] [20] Collectively, the interactions of signaling proteins with PSD95 are enabled by 3 postsynaptic density-95, discs large, zonula occludens-1 (PDZ) domains, which act as docking sites for signaling molecules and show preference for distinct binding partners ( Figure 1A ). PDZ1 and PDZ2 preferentially bind to the C terminus of the K V 1.2α subunit via an association that is intrinsically unstable, thereby permitting a dynamic and reversible interaction. 17, 19, 23, 24 Src-homology and guanylate kinase domains also interact with other scaffolding proteins, such as guanylate kinase-associated protein or A-kinase anchoring protein (AKAP), providing a platform for macromolecular complexes. 21, 25, 26 Because the 3 PDZ domains of PSD95 can form interactions with several signaling molecules, the design of interfering peptides that disrupt the interaction between PSD95 and a specific molecular partner has emerged as an important strategy to pinpoint the physiological impact of a single scaffolding interaction. 27, 28 In this approach, a dominantnegative peptide of identical sequence to the PDZ-binding motif of a molecular partner is overexpressed to disrupt this PDZ interaction only. The importance of PSD95 scaffolding of N-methyl-d-aspartate receptors (NMDARs) and neuronal nitric oxide synthase in neurons was revealed using this strategy. 27, 28 A similar dominant-negative peptide was administered to rodents and nonhuman primates in vivo to reduce neuronal damage after experimental stroke by disrupting PSD95-dependent excitotoxic signaling between NMDAR and neuronal nitric oxide synthase. To achieve optimal cell penetration in these studies, an HIV-tat sequence was coupled to the C terminus peptide sequence of the NMDAR-NR2B subunit that binds to PDZ domains. [29] [30] [31] [32] In the present study, we adopted this general strategy to evaluate whether association with PSD95 is required for the proper function of K V 1 channels in rat CA and to identify other components in the PSD95 complex that also may be required to confer cerebral vasodilation. We designed a cell-permeable dominant-negative peptide corresponding to the C terminus PDZ motif of the K V 1.2-subunit (K V 1-C peptide) to disrupt K V 1 scaffolding by PSD95. Our findings draw attention to PSD95 as a key scaffolding protein in cVSMCs that enables the basal phosphorylation and opening of K V 1 channels to contribute to the resting diameter of CA and infer that conditions that interrupt the PSD95 complex may compromise cerebral vasodilation and blood flow.
Methods
CAs were isolated from 10-to 14- week-old male Sprague-Dawley rats as approved by the University of Arkansas for Medical Sciences Institutional Animal Care and Use Committee. A dominant-negative peptide (K V 1-C) was used to disrupt the association of K V 1 and PSD95 ( Figure 1B ). K V 1-C consists of the final 10 amino acids of the C terminus of K V 1.2α attached to an N terminus HIV-tat sequence (NH 3 -YGRKKRRQRRR) to confer membrane permeability. An N terminus fluorescein label was attached to some peptides for
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A-kinase anchoring protein CA cerebral artery cVSMC cerebral vascular smooth muscle cell visualization. Two scrambled variations of the peptide were used as negative controls (21st Century Biochemicals). Peptide disruption of K V 1 channel-PSD95 association was determined by coimmunoprecipitation. 16 Protein surface expression was determined by biotinylation. 33 CA diameter was measured using a pressure myograph and software (Danish Myo Technology). In situ response of middle cerebral arterioles to local application of peptides was measured by suffused cranial window imaging using a Sony HDR-PJ580 camera and an automated IPLab script. Membrane potential was measured by glass microelectrodes connected to a preamplifier (DAGAN) and analyzed by WinDaq Lite software (DATAQ). Whole-cell cVSMC patch-clamp was performed with an EPC 7 amplifier (HEKA) and pCLAMP 6 software (Molecular Devices). 16 Nonpermeable peptides without the HIV-tat (GenScript) were used for patch-clamp experiments. Images were obtained using a confocal microscope. 16 Data are presented as mean±SEM. P<0.05 was considered statistically significant. An expanded Methods section is available in the Online Data Supplement.
Results

Cell-Permeable K V 1-C Peptide Disrupts the Interaction of K V 1.2α and PSD95 in cVSMCs
K V 1 channel and PSD95 association ( Figure 1A ) was targeted for disruption using a peptide (K V 1-C), which couples an N terminus HIV-tat sequence to the last 10 amino acid sequence of the K V 1.2α C terminus that contains a class I PDZ-binding motif, LTDV ( Figure 1B ). To ensure specificity of the K V 1-C peptide, a scrambled peptide (Scm) sharing the same amino acid composition as K V 1-C but randomly ordered was used as control ( Figure 1B ). In isolated CA, incubation for 30 minutes with K V 1-C peptide disrupted the K V 1.2α-PSD95 interaction as evidenced by a loss of immunoreactive signal for PSD95 in anti-K V 1.2α immunoprecipitate compared with arteries incubated with Scm peptide ( Figure 1C , lanes 1 and 2). A corresponding increase in the PSD95 band was observed in the flow-through fraction that did not bind to K V 1.2α antibody ( Figure 1C , lanes 3 and 4). As previously reported, 16 only the full form of PSD95 (upper band at 95 kDa) associates with the K V 1.2α subunit. To examine the effect of K V 1-C peptide on the plasma membrane expression of K V 1 channels, isolated arteries were treated with Scm or K V 1-C peptides, biotinylated and analyzed by Western blot. 33 In the resulting Western blot, the bulk of K V 1.2α-containing channels were found in the biotinylated surface fraction compared with the nonbiotinylated cytosolic fraction ( Figure 1D ). The surface expression of K V 1.2α subunits was not different between arteries exposed to K V 1-C compared with Scm, indicating that K V 1-C did not cause a loss of surface K V 1 channels ( Figure 1D ). We also confirmed that K V 1-C peptide penetrated cVSMCs of intact arteries using confocal imaging ( Figure 2 ). After 1 minute of incubation, fluorescein-labeled K V 1-C peptide appeared at the cell surface and a strong fluorescent signal was observed intracellularly by 3 minutes that persisted until 30 minutes. Similar penetration patterns were observed for fluorescein-labeled Scm peptide (Online Figures I and II) . Compared with smooth muscle cells, neurons in the adventitia and the endothelial cells absorbed the peptides sooner, within the first minute (Online Figure I) . Collectively, these findings indicate that our cell-permeable dominant-negative peptide successfully competes with the native K V 1.2α subunit to prevent its binding to the PDZ domains of PSD95, and it provides a tool to disrupt the association between K V 1 channels and PSD95 in cVSMCs of intact arteries.
K V 1-C Peptide Constricts and Depolarizes Isolated CA
Diameter recordings of isolated, pressurized rat CA exposed to K V 1-C peptide revealed a rapid constriction of CA in response to disruption of the K V 1 channel-PSD95 complex, whereas Scm peptide did not affect vessel diameter ( Figure 3A ). Increasing concentrations of 1-, 3-, and 10-μmol/L K V 1-C peptide progressively reduced CA diameter by −7.4±2.0%, −19.3±2.5%, and −20.3±2.1% ( Figure 3B ). The corresponding values for Scm peptide were −4.2±2.8%, −3.7±0.6%, and −3.9±1.9%. A second scrambled control peptide (Scm2) also did not significantly constrict CA (Online Figure III) . Bath application of the K V 1 channel blocker, 5-(4-phenylalkoxypsoralen) (Psora4) 2,16,34,35 did not further reduce the diameter of arteries already constricted by K V 1-C peptide ( Figure 3C and 3D). Notably, the constrictor response to 100-nmol/L Psora4 was not different from the constriction caused by 10-μmol/L K V 1-C peptide ( Figure 3D ) or the diameter change induced by combined Psora4 and K V 1-C peptide ( Figure 3D ). Absolute diameter values are provided in the Online Figure IV . The constriction induced by K V 1-C peptide was not significantly altered by the presence of 100-μmol/L Nω-Nitro-l-arginine methyl ester and 10-μmol/L indomethacin in the bath solution to block nitric oxide synthase and cyclooxygenase, respectively (Online Figure V) . Constrictor responses to 1-μmol/L linopirdine, a K V 7 channel blocker, or 30-μmol/L BaCl 2 , a K IR channel blocker, were not significantly altered by the presence of 3-μmol/L K V 1-C peptide (Online Figure VI ). In addition, 1-μmol/L glibenclamide, a K ATP channel blocker, or 30-nmol/L stromatoxin, a K V 2.1 channel blocker, did not constrict pressurized CA significantly (n=5 each, data not shown). Importantly, microelectrode recordings indicated that cVSMCs of pressurized CA depolarized from a resting membrane potential (E m ) of −47.6±2.1 to −35.2±3.2 mV in response to 10-μmol/L K V 1-C peptide ( Figure 4A and 4C), a finding consistent with a loss of hyperpolarizing K + current. In contrast, cVSMCs in arteries treated with Scm peptide showed no significant change in resting E m ( Figure 4B and 4C). The addition of 60-mmol/L KCl to bath solutions already containing K V 1-C or Scm peptide further depolarized arteries of both groups to similar values ( Figure 4 ). These findings indicate that the specific disruption of K V 1.2 channel-PSD95 association in pressurized CA leads to depolarization and constriction from the resting tone. These effects seem to correspond selectively to the blockade of K V 1.2 channels and imply a loss . Membrane-permeable peptide mimicking K V 1.2α C-terminus (K V 1-C) causes depolarization of in situ cerebral vascular smooth muscle cells (cVSMCs). A and B, Recordings of cerebral artery (CA) diameter and membrane potential (E m ) in rat CA exposed to K V 1-C (A) or scrambled (Scm; B) peptide. After recording baseline E m (1, 4), 10-μmol/L K V 1-C (2), or Scm (5) peptide was added to the bath followed by 60-mmol/L KCl (3, 6) to elicit maximal depolarization. E m was recorded in each step for ≈5 minutes as indicated by the numbered boxes in the diameter trace. C, Average E m values in the presence of K V 1-C peptide or Scm peptide only, and after the further addition of 60-mmol/L KCl (n=6 each). a to c, Significantly different, P<0.05. Figure 3 . Membrane-permeable peptide mimicking K V 1.2α C-terminus (K V 1-C) disrupts association of postsynaptic density-95 (PSD95) and K V 1.2 and constricts cerebral arteries (CA). A, Representative recording of outer diameter in a cannulated, pressurized (80 mm Hg) rat CA. The artery was initially exposed to 10-μmol/L scrambled (Scm) peptide, and then after extensive washes, exposed to 10-μmol/L K V 1-C peptide. B, CA constricted in response to K V 1-C peptide in a concentration-dependent manner, but did not constrict to Scm peptide (n=5 each). *Significant different from Scm, P<0.05. C, Diameter recordings from a CA exposed sequentially to 10-μmol/L K V 1-C peptide and the specific K V 1 channel antagonist, 100-nmol/L 5-(4-phenylalkoxypsoralen) (Psora4). D, Percentage change in diameter from baseline in response to 10-μmol/L K V 1-C peptide and 100-nmol/L Psora4 (n=6 each). *Significantly different from Scm, P<0.05.
of function of K V 1.2 channels in cVSMCs when dissociated from the PSD95 complex.
K V 1-C Peptide Constricts CA In Vivo
After confirming the selective disruption of K V 1-PSD95 interaction ex vivo by K V 1-C peptide, we evaluated the impact of K V 1-C peptide on CA in vivo. A partial craniectomy of the right parietal plate of anesthetized rats immobilized in a stereotaxic frame, followed by mounting of a cranial window, exposed branches of the middle CAs for imaging and topical peptide treatment ( Figure 5A ). Suffusion of the cranial window with 30-μmol/L K V 1-C peptide resulted in a rapid constriction of CA, which was sustained for ≥20 minutes ( Figure 5B and 5C). Average values indicated that middle CAs treated with K V 1-C peptide showed a significant reduction in diameter of −16.1±3.9% by 5 minutes with maximum constriction at 15 minutes averaging −16.8±3.5% ( Figure 5D ). In contrast, the same concentration of Scm peptide did not affect vessel diameter ( Figure 5B and 5C ), although the same arteries responded to 60-mmol/L KCl by strongly constricting as evidence of viability ( Figure 5B ). Arteries in physiological salt solution or Scm peptide showed a small decrease in diameter by 15 minutes, which were not statistically significant from each other ( Figure 5D ). These results provide initial evidence that K V 1 channels in PSD95 signaling complexes contribute to the resting diameter of cerebral resistance arteries in vivo and disruption of such association may have a profound effect on cerebral blood flow.
K V 1-C Peptide Suppresses Psora4-Sensitive K + Currents in cVSMCs
Next, we used patch-clamp techniques to confirm that K V 1-C peptide directly reduces K V 1 channel function in cVSMCs. In these studies, nonpermeable peptides were added to the dialyzing pipette solution after extensive attempts to add permeable HIV-tat-containing peptides extracellularly resulted in disruption of high-resistance gigaohm seals. Accordingly, control K + currents were recorded from cVSMCs dialyzed with either 3-μmol/L Scm nonpermeable ( Figure 6A ) or 3-μmol/L K V 1-C nonpermeable ( Figure 6B ) before addition of the selective K V 1 channel blocker, 100 nmol/L Psora4. 2, 16, 34, 35 Digital subtraction of post-Psora4 (+Psora4) from pre-Psora4 (-Psora4) recordings provided an estimation of Psora4-sensitive K V 1 current ( Figure 6C , I Psora ). The residual currents were regarded as Psora4-insensitive ( Figure 6D , I other ). The peak I Psora density at +58 mV was 8.47±1.29 pA/pF for Scm nonpermeable-treated cells. This value decreased by 45% to 4.65±0.71 pA/pF for cells dialyzed with K V 1-C nonpermeable ( Figure 6C ). In contrast, the peak density of residual Psora4-insensitive current (I other ) was not significantly different between Scm and K V 1-C-treated cells ( Figure 6D ). These findings concur with reports that only K V 1α subunits have PDZ-binding motifs to enable PSD95 interaction. 16, 17 In this regard, Shab-type K V 2 channels and KCNQ (K v 7) channels likely contribute to the Psora4-insensitive residual current. Stromatoxin-sensitive K V 2 channels are not blocked by Psora4 in cVSMCs 16, 35 and Psora4 does not compromise vasoconstrictor responses of CA to the K V 7 channel blocker, linopirdine (Online Figure VI) .
K V 1-C Peptide Reduces PKA Phosphorylation of K V 1 Channels
After demonstrating that PSD95 is the critical scaffold required for K V 1 channel function and dilation of CA, we searched for the molecular component(s) of the PSD95 signaling complex responsible for the basal opening of K V 1 channels. One candidate binding partner of PSD95 is AKAP150, which is known to act as a focal point in multiprotein signaling complexes to facilitate PKA-dependent phosphorylation of target proteins. 26 Huang et al 10 first reported that direct application of PKA catalytic subunits lead to the activation of cloned cardiac K V 1 channels in oocytes. Later, PKA-dependent phosphorylation and opening of K V 1 channels were reported in native smooth muscle cells from rabbit portal vein 11 and canine colon. 12 However, many later studies using cAMP analogues or forskolin on recombinant K V 1.2 channels in heterologous cells only revealed an increase in K V 1.2 protein levels by PKA phosphorylation with small to no increase in gating of channels. [13] [14] [15] 36 Therefore, we examined whether the association of K V 1 channels with PSD95 signaling complex could explain this apparent discrepancy.
Previously, Connors et al 14 successfully used an antibody that detects PKA-phosphorylation of serine or threonine residues to identify PKA phosphorylation of rat K V 1.2α subunits overexpressed in a heterologous expression system. We used the same antibody to explore whether K V 1.2α subunit-PSD95 interaction is required for PKA-phosphorylation of K V 1 channels in cVSMCs, thereby inferring colocalization of K V 1 channels with AKAP150 in the vascular PSD95 signaling complex. CAs treated with 10-μmol/L Scm or K V 1-C peptide for 30 minutes were lysed and loaded equally (30 μg) into lanes of a Western blot probed with anti-phospho-PKA substrate. 14 Compared with CA treated with Scm peptide, K V 1-C-treated CA showed a marked loss in the phosphorylation of the ≈75 kDa band ( Figure 7A, left blot) , which is the fully glycosylated form of K V 1.2α 1 required for PKA phosphorylation. 9 Average densitometric values from 5 similar preparations demonstrated a ≈50% reduction in PKA phosphorylation of K V 1.2α, whereas the expression level of total K V 1.2α protein did not change significantly ( Figure 7A , left panel and Figure 7B ). These results suggest that PSD95 scaffolding promotes PKA-mediated phosphorylation of K V 1 channels, an event associated with increased K V 1 channel opening.
To confirm that reduced PKA-mediated phosphorylation of K V 1 channels contributed to the constriction of CA by K V 1-C peptide, we intervened to preserve channel phosphorylation using low concentrations of the protein serine/threonine phosphatase inhibitors, okadaic acid (OA, 300 nmol/L) and calyculin-A (100 nmol/L). Neither phosphatase inhibitor significantly altered the resting arterial diameter of isolated CA ( Figure 8B ), but both significantly blunted the constrictor response to K V 1-C peptide ( Figure 8A and 8B) . In drug-free physiological salt solution, K V 1-C peptide reduced the diameter of CA by −19.5±1.6% compared with −9.3±3.3% and 914.1±1.1% in the presence of okadaic acid and calyculin-A, respectively ( Figure 8B ). Constriction in response to KCl was not altered by the presence of okadaic acid or calyculin-A ( Figure 8C) , indicating that the ability of CA to constrict was not nonspecifically reduced by the presence of low concentrations of phosphatase inhibitors. In a final set of experiments we verified that a loss of PKA activity results in constriction of rat CA because earlier studies defining mechanisms of PKA modulation of K V 1 channel properties were mostly performed in cell systems. 11, 12 Indeed, 1-μmol/L myristoylated protein kinase A inhibitor peptide rapidly constricted isolated rat CA by −27.3±0.7%, and this constrictor response was significantly reduced in the presence of 100-nmol/L calyculin-A ( Figure 8D and 8E) . These findings highlight that PKA phosphorylation of K V 1 channels is an important contributor to the basal dilation of CA and that a dynamic association with the PSD95 signaling complex is critically required for PKA phosphorylation of K V 1 channels in CA.
Discussion
PSD95 was originally regarded as an exclusive feature of the postsynaptic density in neurons, and it was only rarely detected in nonneural tissues. 37, 38 However, two recent reports identified PSD95 as a potentially important scaffold of K V 1 channels in lymphocytes and in cVSMCs. 16, 39 First, mutation of the K V 1.3 subunit PDZ-binding motif or knockdown of PSD95 in T lymphocytes inhibited the recruitment of K V 1.3 into contact points on the cell surface, implying an important role of PSD95-K V 1 channel interaction in T-cell activation. 39 Second, we demonstrated in cVSMCs that PSD95 is expressed and antisense knockdown of PSD95 in rat CA for 72 hours results in a concomitant loss of K V 1 channel protein and vasodilator function. These findings suggested a critical role of PSD95 in maintaining the expression of K V 1 channels in the cerebral circulation. 16 However, because K V 1 channels were downregulated by PSD95 knockdown in our previous study, the impact of PSD95 signaling complex on K V 1 channel function could not be assessed. Furthermore, knockdown of PSD95 effectively limits interaction with all of its binding partners, potentially disrupting multiple signaling pathways in addition to K V 1 channels involved in regulating the diameter of CA. For example, β1-adrenergic receptors, 40 serotonin receptors, 41 inward-rectifying potassium channels, 42 and neuronal nitric oxide synthase 43 are known binding partners of PSD95 in neurons that could similarly interact with PSD95 in arteries to alter vascular tone. Thus, the present study designed a dominant-negative peptide to specifically disrupt the scaffolding interaction between K V 1 channels and PSD95 in cVSMCs. Our results provide initial evidence that the PSD95 signaling complex is critically required for K V 1 channel dilator function in rat CA in situ and further suggest that PSD95 Figure 7 . Protein kinase A (PKA) phosphorylation of K V 1.2α is reduced in arteries exposed to membrane-permeable peptide mimicking K V 1.2α C-terminus (K V 1-C). A, Western blot using a phospho-PKA substrate antibody (PKAph, left blot) detected a ≈75-kDa protein corresponding to K V 1.2α in cerebral artery (CA) protein lysates. CA from age-matched rats were incubated in either scrambled (Scm) or K V 1-C peptide, and then lysates (30 μg) were loaded into adjacent lanes. Lanes 1 to 2 and lanes 3 to 4 represent separate preparations. The blot was stripped and reprobed with anti-K V 1.2α antibody (K V 1.2α, right blot) . B, Densitometry measurement of PKAph and K V 1.2α bands relative to Scm treatment (n=5). *Significantly different from Scm, P<0.05. Figure 8 . Phosphatase inhibitors blunt the vasoconstriction caused by membrane-permeable peptide mimicking K V 1 channel C terminus (K V 1-C). A, Representative traces show that the phosphatase inhibitors, 300-nmol/L okadaic acid (OA) and 100-nmol/L calyculin A (CalA), blunt the vasoconstrictor response of rat cerebral artery (CA) to K V 1-C peptide. B, Average percentage change in diameter in response to vehicle (veh), OA, CalA, 3-μmol/L K V 1-C peptide, or K V 1-C peptide in the presence of veh, OA, or CalA (n=5-10). The phosphatase inhibitors did not affect the resting diameter of CA, but blunted the vasoconstrictor response to K V 1-C peptide. a to c: statistical significance, P<0.05. C, Average percentage change in diameter caused by 60-mmol/L KCl in the presence and absence of a phosphatase inhibitors (n=4-10). No significant difference between groups. D, Representative traces show that 100-nmol/L CalA blunts the vasoconstrictor response to 1-μmol/L protein kinase A inhibitor peptide (PKI). E, Average percentage change in diameter caused by 1-μmol/L PKI in the absence or presence of CalA (n=5). *Significantly different from PKI alone, P<0.05. provides a platform for interaction between PKA and K V 1 channels that enables PKA-mediated phosphorylation and opening of K V 1 channels to promote hyperpolarization and relaxation of cVSMCs.
Our initial experiments explored whether a dynamic association with PSD95 was required for the proper vasodilator function of K V 1 channels in CA. After directly disrupting the K V 1-PSD95 association by application of K V 1-C peptide, we observed a rapid and profound vasoconstriction ex vivo and in vivo. Ex vivo K V 1-C peptide-induced constriction was equivalent to constriction caused by the K V 1 channel blocker Psora4 and there were no additive effects of concomitant treatment, whereas vasoconstriction caused by K V 7 channel blocker linopirdine or K IR channel blocker BaCl 2 was not altered by K V 1-C peptide. Psora4 is a highly selective blocker of K V 1 channels and does not significantly block other voltage-gated K + channels or large-conductance, Ca 2+ -activated K + channels. 2, 16, 34, 35 A recent report identified a secondary binding site in the unique side pocket of K V 1 channels that strengthens the selectivity of Psora4. 35 In our patch-clamp study, K V 1-C peptide caused a significant reduction in Psora4-sensitive K + currents, whereas Psroa4-insensitive K + currents that may contain K V 2.1 or K V 7 currents remained identical to Scm-treated cells. Considering the diversity of K + channels in CA, the effects caused by disruption by K V 1-C peptide is remarkably specific to the blockade of K V 1 channels and strengthens the idea of selective PDZ binding of K V 1 channels to the PSD95 complex.
Application of K V 1-C peptide to isolated CA also depolarized the cVSMC membrane without an apparent change in K V 1 channel expression, implying that basal K V 1 channel opening relies on PSD95 scaffolding to mediate hyperpolarizing K + efflux. The rapid onset of K V 1-C peptide-induced effects was consistent with the idea that the intrinsic instability of the C terminus of the K V 1.2α subunit allows for a dynamic interaction with the PDZ-binding domains of PSD95. 24 In general, PDZ binding seems to be reversible and similar competing peptides have been applied to cultured neuronal cells 28 and to neurons in vivo [30] [31] [32] to disrupt the binding of NMDAR and PSD95 and break the excitotoxic signaling pathway mediated by PSD95. The rapid intracellular delivery of peptides conferred by the HIV-tat sequence has been reported in many cell types 44 and now successfully used in the present study to explore ion channel signaling pathways in arteries. Considering our finding that an HIV-tat-conjugated peptide targeting PSD95 can markedly alter cerebral vascular tone, it is possible that the vasoconstrictor effects of an HIV-tat peptide delivered intravenously by Bach et al 30 and Cook et al 31 to interrupt NMDAR-PSD95 interaction in neurons and ameliorate stroke may have a direct action on cVSMCs as an unexpected side effect. Because K V 1.2α and NMDAR share the PDZ1 and PDZ2-binding domains of PSD95, 30 C terminus peptides designed for NMDAR can potentially cross-compete with K V 1 channels for binding to PSD95. Considering this therapy is already in phase 1 and 2 clinical trials in Canada and the United States, the need to fully define the physiological role of PSD95 in CA is even more urgent. In this respect, the present study provides initial proof for mechanism by which disruption of PSD95 scaffolding could adversely affect cerebral circulation.
We also observed that K V 1-C peptide reduced PKA phosphorylation of K V 1 channels without altering cell surface expression. Our study indicates that association with the PSD95 complex is required for the direct PKA-mediated phosphorylation of K V 1.2α subunit and increased channel function independent of expression level. Our observation may explain the dichotomy between early reports of PKA-induced increase in K V 1.2 channel activity [10] [11] [12] and the lack of such increase in K V 1.2 channel activity in many later studies in heterologous expression systems. [13] [14] [15] This apparent discrepancy may have resulted from the lack of PSD95 signaling complex in heterologous cells, which is necessary to hold PKA in proximity to K V 1.2 channels for proper phosphorylation. In seeming contrast to the present study, we previously reported that antisense-knockdown of PSD95 in rat CA for 72 hours results in marked loss of the K V 1.2α protein. 16 However, in the present study, CAs were only exposed to the K V 1-C peptide for 30 minutes, a time frame that apparently was too short to cause a loss of K V 1 channels and only their vasodilator function was significantly blunted. The finding that PSD95 is required for PKA-mediated phosphorylation of the K V 1.2α subunit in cVSMCs raises the possibility that PSD95-AKAP interaction exists as unrecognized scaffolding machinery in the vasculature. Colledge et al 26 reported that PSD95-AKAP interaction is required for PKA-dependent phosphorylation of AMPA receptors in neurons, and our data suggest that the PSD95-AKAP complex also may be required for PKA-dependent phosphorylation of vascular K V 1 channels. Dissociation of K V 1.2α-containing channels from this complex by the K V 1-C peptide may reduce subunit phosphorylation leading to phosphatase-dependent dephosphorylation, less channel opening, depolarization of the cell, and constriction of CA.
Several limitations of our study should be acknowledged. First, we have used nonpermeable peptides in patch-clamp studies to verify that K V 1-C peptide disruption of PSD95-K V 1 interaction reduces K V 1 channel-mediated K + current. Standard whole-cell and perforated-patch studies were attempted with the cell-permeable peptides, but application of the HIV-tat peptide even in low concentrations consistently disrupted gigaohm seals. Thus, apparently the HIV-tat sequence that contains several positive charges interferes with seal integrity. For this reason, we also performed membrane potential measurements to provide strong evidence that K + efflux through K V 1 channels is attenuated by K V 1-C peptide disruption of the K V 1 channel-PSD95 complex. Second, we used a higher concentration of K V 1-C peptide for in vivo than ex vivo studies of vascular reactivity. Isolated CA constricted maximally to 10-μmol/L K V 1-C peptide, but 30-μmol/L K V 1-C was required to elicit sustained constriction in vivo (Online Figure VII) . In contrast to isolated perfused arteries, a reduction in peptide potency and efficacy may be expected in vivo, because the cranial window preparation unavoidably has adventitia and neural tissue as barriers or sinks of peptide, potential peptide loss through cerebrospinal fluid or metabolism may occur, and compensatory mechanisms may exist to normalize arterial diameter in response to disruption of normal homeostatic mechanisms. Third, we did not identify which serine or threonine residues of K V 1.2α subunit are targets of PSD95mediated PKA phosphorylation in cVSMCs and left this line of inquiry for future studies. Finally, K V 1-C peptide may have unidentified nonspecific effects in CA. Our K V 1-C peptide corresponding to a PDZ-binding motif on the K V 1.2α subunit was designed to act as a dominant-negative peptide to compete for the PDZ1 and PDZ2 domains on PSD95. Of the known voltage-gated K + channel subunits in CA, K V 1.2α is uniquely equipped with a PDZ-binding motif, 16 which may enable the K V 1 channels to be downstream targets of PKA-dependent signaling on the PSD95 scaffold. However, the PDZ domains of PSD95 also could bind unidentified vasoactive proteins in CA that contain a PDZ-binding motif. In addition to K V 1.2α, these proteins also could be displaced by the K V 1-C peptide, thereby potentially modifying arterial diameter.
In summary, we propose that the scaffolding of K V 1 channels by PSD95 in CA is a dynamic interaction required for the efficient vasodilator function of K V 1 channels through PKA phosphorylation. Dissociation of K V 1 channels from this complex by a dominant-negative peptide causes rapid vasoconstriction of CA ex vivo and in vivo. Our findings emphasize that therapeutic targeting of PSD95 to reduce cytotoxic injury caused by stroke or other ischemic insults should consider that manipulation of PSD95 also may critically alter cerebral arterial diameter and blood flow independently of neuronal function. Similarly, disease-based alterations of PSD95 structure or function may potentially contribute to cerebral blood flow abnormalities by disrupting K V 1 channel dilator function or interfering with the roles of other PSD95binding partners in VSMCs.
